<DOC>
	<DOCNO>NCT02446925</DOCNO>
	<brief_summary>The Surefire Infusion System novel catheter initially develop prevent reflux embolic material non-target vascular territory . Further research demonstrate improved penetration distribution embolic material treat arterial territory . The purpose study compare Y-90 glass microsphere distribution penetration cancerous tissue within liver standard endhole catheter Surefire Infusion System .</brief_summary>
	<brief_title>Surefire Catheter Versus Standard End-hole Microcatheter : A Pilot Study</brief_title>
	<detailed_description>Yttrium-90 ( Y-90 ) radioembolization minimally invasive trans-arterial treatment primary secondary hepatic malignancy rely tumor hypervascularity concentration radioactive microspheres . The Surefire® Infusion System ( SIS ) ( Westminster , CO ) develop reduce non-target embolization result morbid complication , especially involve radioembolic drug elute microspheres . Prior introduction , radioembolization trans-arterial therapy perform standard end-hole catheter . In addition provide protection non-target embolization , study demonstrate improved penetration embolic material ( tantalum microspheres Tc-99M label MAA ) use SIS compare conventional end-hole catheter . To date , study demonstrate improved distribution penetration yttrium-90 glass microspheres use Surefire catheter versus standard end-hole catheter . Y-90 distribution evaluate use immediate post-delivery PET/CT imaging create pair production image immediate post delivery period . PET/CT demonstrate distribution dose tumor calculate . The investigator propose pilot study compare yttrium-90 tumor distribution concentration patient hepatocellular carcinoma ( HCC ) use SIS versus standard end-hole catheter .</detailed_description>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Lobaronly treatments Patients biopsy radiographically proven hepatocellular carcinoma candidate transplant , surgical resection ablative therapy Patients 18 year age old Patients able provide write informed consent Patients BarcelonaClinic Liver Cancer ( BCLC ) Stage C disease , Patients Eastern Cooperative Oncology Group ( ECOG ) performance status ≥ 3 , Patients unable tolerate Y90 , Patients arterial anatomy unsuitable place Surefire catheter , Patients uncorrectable coagulopathy , Patients platelets less 50 ( uncorrectable ) , Bilirubin &gt; 3 mg/dl , AST ALT &gt; 5x upper limit normal , Patients unable tolerate angiography , Patients &lt; 3 month live , Patients meet standard Y90 exclusion criterion accord package insert Female patient pregnant Patients age 18 Patients unable provide write informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>